Unión Europea - español - EMA (European Medicines Agency)

theravia - dexametasona - mieloma múltiple - corticosteroides para uso sistémico - tratamiento del mieloma múltiple.

Unión Europea - español - EMA (European Medicines Agency)

merck sharp & dohme b.v. - fosfato de tedizolid - soft tissue infections; skin diseases, bacterial - antibacterials for systemic use, , other antibacterials - sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and adolescents 12 years of age and older.

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - fumarato de dimetilo - la esclerosis múltiple remitente-recurrente - inmunosupresores - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - relugolix - neoplasmas prostáticos - terapia endocrina - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Unión Europea - español - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - mieloma múltiple - agentes antineoplásicos - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Unión Europea - español - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mieloma múltiple - agentes antineoplásicos - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Unión Europea - español - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - esclerosis múltiple - inmunosupresores selectivos - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Unión Europea - español - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Unión Europea - español - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - la esclerosis múltiple remitente-recurrente - inmunosupresores - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - la esclerosis múltiple remitente-recurrente - los inmunosupresores selectivos de inmunosupresores - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).